#ASCO14 - Poster: Safety results of the enzalutamide expanded access program in the United States and Canada for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel

CHICAGO, IL USA (UroToday.com) - Presented by Anthony M. Joshua,1 Neal Shore,2 Fred Saad,3 Kim N. Chi,4 Carl A. Olsson,5 Urban Emmenegger,6 Mark Scholz,7 William Berry,8 Som D. Mukherjee,9 Eric Winquist,10 Naomi B. Haas,11 Nahla Hasabou,12 Carl Dmuchowski,12 Frank Perabo,12 Mohammad Hirmand,13 Margaret A. Foley,12 and Dana Rathkopf,14 for The Enzalutamide Expanded Access Study Investigators at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

asco 2014 joshua poster thumb

1University Health Network/Princess Margaret Cancer Centre, Toronto, ON, Canada
2Carolina Urologic Research Center, Myrtle Beach, SC, USA
3University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada
4British Columbia Cancer Agency–Vancouver Cancer Centre, Vancouver, BC, Canada
5Columbia University Medical Center and Integrated Medical Professionals, New York, NY, USA
6Sunnybrook Odette Cancer Centre, Toronto, ON, Canada
7Prostate Oncology Specialists Inc., Marina del Rey, CA, USA
8US Oncology Inc., Cancer Centers of North Carolina, Raleigh, NC, USA
9Juravinski Cancer Centre, Hamilton, ON, Canada
10Western University–London Health Sciences Centre, London, ON, Canada
11Abramson Cancer Center, Philadelphia, PA, USA
12Astellas Pharma Global Development, Northbrook, IL, USA
13Medivation Inc., San Francisco, CA, USA
14Memorial Sloan Kettering Cancer Center, New York, NY, USA

 

 

email news signup